Leukemic cell proliferation

Leukemic cell proliferation is the pathological process characterized by the rapid, uncontrolled division and expansion of malignant hematopoietic progenitor cells. This process is the fundamental driver of leukemia, leading to the overcrowding of the bone marrow and the displacement of healthy blood cells, which results in clinical manifestations such as anemia, infection, and bleeding (National Cancer Institute, 2023). Proliferation is typically fueled by genetic alterations such as chromosomal translocations (e.g., the Philadelphia chromosome) or mutations in signaling proteins like FLT3, KIT, or RAS, which provide constitutive growth signals (Nature Reviews Cancer, 2020). Therapeutic intervention aims to arrest this proliferation through various modalities, including targeted inhibitors of specific oncogenic drivers, cytotoxic chemotherapy, and pro-apoptotic agents (PubMed, 2022). Because it is a complex biological outcome rather than a single protein or receptor, leukemic cell proliferation serves as a key phenotypic endpoint for evaluating drug efficacy in both preclinical research and clinical oncology (Blood Journal, 2021). Monitoring proliferation rates via biomarkers like Ki-67 or blast counts is essential for determining patient prognosis and response to therapy (StatPearls, 2023).

Other names

Leukemia cell growthLeukemic blast expansionMalignant hematopoietic cell proliferation

Inhibition of leukemic cell proliferation is achieved through various mechanisms including tyrosine kinase inhibition (e.g., BCR-ABL, FLT3), induction of apoptosis (e.g., BCL-2 inhibition), DNA synthesis inhibition (antimetabolites), and epigenetic modulation (IDH1/2 inhibitors).